Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 725 of 923 entries
View as:
Phase: N/A
Priority: Normal
Start: 10/08/15
End: 02/28/18
Due: 02/28/19
Phase: N/A
Priority: Normal
Start: 09/30/10
End: 12/31/11
Due: 12/31/12
Phase: N/A
Priority: Normal
Start: 03/31/18
End: 07/31/18
Due: 07/31/19
Phase: N/A
Priority: Normal
Start: 12/31/08
End: 07/31/09
Due: 07/31/10
Phase: N/A
Priority: Normal
Start: -
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 02/28/10
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 08/31/11
End: 12/31/24
Due: 12/31/25
Phase: N/A
Priority: Normal
Start: 06/30/12
End: 02/29/16
Due: 02/28/17
Phase: N/A
Priority: Normal
Start: 05/14/15
End: 12/31/20
Due: 12/31/21
Phase: N/A
Priority: Normal
Start: 05/31/17
End: 12/31/19
Due: 12/31/20
Phase: N/A
Priority: Normal
Start: 11/30/09
End: 06/30/14
Due: 06/30/15
Phase: N/A
Priority: Normal
Start: 02/21/16
End: 11/30/21
Due: 11/30/22
Phase: N/A
Priority: Normal
Start: 01/31/12
End: 12/31/18
Due: 12/31/19
Phase: N/A
Priority: Normal
Start: 03/31/10
End: -
Due: -
Development of Escitalopram Genomic Device by Using Candidate Gene Approach and Genome-Wide Scanning
Phase: N/A
Priority: Normal
Start: 12/31/08
End: 12/31/16
Due: 12/31/17
Phase: N/A
Priority: Normal
Start: 05/01/23
End: 12/31/23
Due: 12/31/24
Phase: N/A
Priority: Normal
Start: 10/31/13
End: 02/28/14
Due: 02/28/15
Phase: N/A
Priority: Normal
Start: 04/30/12
End: 12/31/12
Due: 12/31/13
Phase: N/A
Priority: Normal
Start: 02/08/17
End: 06/30/22
Due: 06/30/23
Phase: N/A
Priority: Normal
Start: 04/08/15
End: 10/30/21
Due: 10/30/22
Phase: N/A
Priority: Normal
Start: 01/18/21
End: 01/31/25
Due: 01/31/26
Phase: N/A
Priority: Normal
Start: 01/17/22
End: 03/22/24
Due: 03/22/25
Phase: N/A
Priority: Normal
Start: 09/18/23
End: 12/31/29
Due: 12/31/30
Phase: N/A
Priority: Normal
Start: 09/18/17
End: 12/31/19
Due: 12/31/20
Phase: N/A
Priority: Normal
Start: 07/31/06
End: -
Due: -